Abstract
Since the first human gene therapy clinical trials were proven successful in 2000, human gene therapy has witnessed setbacks as well as encouraging progress. While these first clinical trials were performed with a γ-retrovirus vector to correct X-linked severe combined immunodeficiency (SCID-X1) in children, others since then have applied similar or alternative viral vector strategies. More recently, lentiviral vectors have been used for the correction of human β- thalassaemia and adrenoleukodystrophy. They have also been successfully used in the treatment of leukaemia by modifying cytotoxic T cells directed to cancer cells. Here we describe the production of clinical grade retro- and lentiviral vectors for application in human therapy. Keywords: Biosafety, clinical grade lentivector, gene therapy, genotoxicity, GMP guidelines, HIV, immunology, insertional mutagenesis, mutagenesis assay, packaging cell lines, purification, replication competent lentivirus, replication competent retrovirus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Immunology‚ Endocrine & Metabolic Agents in Medicinal Chemistry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
